REDWOOD CITY, Calif.,
June 15, 2017 /PRNewswire/ -- Nevro
Corp. (NYSE: NVRO), a global medical device company that is
providing innovative evidence-based solutions for the treatment of
chronic pain, today announced that Neurosurgery, the
official journal of the Congress of Neurological Surgeons (CNS),
selected the SENZA-RCT 24-month outcomes publication as the
journal's Top Pain Paper of the Year. The SENZA-RCT is a
groundbreaking pivotal study that was both the largest prospective
randomized clinical trial ever conducted to assess the treatment of
chronic back and leg pain, and the first to evaluate comparative
effectiveness of spinal cord stimulation (SCS) therapies.
Each paper was subject to a rigorous review process with the
journal's editorial board, beginning with initial selection from
the entire pool of papers published between June 2016 and June
2017. "The CNS is committed to providing relevant and
informative science to our members. This paper delivers on that
commitment, and improves our field through innovation. This
accomplishment is remarkable and should be celebrated," said Dr.
Alan M. Scarrow, CNS President.
Dr. Todd Sitzman first presented
the 24-month results of the SENZA-RCT during the 2015 North
American Neuromodulation Society (NANS) meeting. The results
showed the sustained superiority of HF10™ therapy versus
traditional low-frequency SCS therapy across all primary and
secondary endpoints—including pain relief in the back and legs, and
functional outcomes at every evaluation point to 24 months.
The Principal Investigator of the trial, Dr. Leonardo Kapural, from Wake
Forest University Baptist Medical Center, will present the
trial results at the 2017 CNS Annual Meeting on Wednesday, October 11, in Boston, MA. "We are excited to have our
manuscript detailing the 24-month outcomes from the SENZA-RCT
selected as the Top Pain Paper of the Year," stated Dr. Kapural.
"The aim of the study was to provide meaningful longitudinal,
comparative evidence that will assist physicians in better
evaluating therapies and determining the best course of treatment
for their patients suffering from chronic pain. It is
humbling that our work received this prestigious award."
"We are truly honored by this recognition from the prestigious
Neurosurgery journal," said Rami
Elghandour, President and CEO of Nevro. "We believe
comparative, prospective long-term RCTs serve as the cornerstone of
advancing patient care. We sincerely appreciate the editorial
board's recognition of the quality of work by Dr. Kapural and the
SENZA-RCT investigators for their groundbreaking study. We
are continuing to invest in rigorous RCTs and look forward to
increasing support for the field with pragmatic Level I
evidence."
Access to the full two-year SENZA-RCT publication, originally
published in the December 2016 issue
of Neurosurgery, can be found here:
https://academic.oup.com/neurosurgery/article/79/5/667/2835700/Comparison-of-10-kHz-High-Frequency-and
About the Congress of Neurological Surgeons
The Congress of Neurological Surgeons is the global leader in
neurosurgical education, serving to promote health by advancing
neurosurgery through innovation and excellence in education. The
CNS provides leadership in neurosurgery by inspiring and
facilitating scientific discovery and its translation into clinical
practice. The CNS maintains the vitality of the profession through
volunteer efforts of its members and the development of leadership
in service to the public, to colleagues in other disciplines, and
to neurosurgeons throughout the world in all stages of their
professional lives. For more information, visit www.cns.org.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on providing innovative products that improve the quality of life
of patients suffering from debilitating chronic pain. Nevro has
developed and commercialized the Senza® spinal cord stimulation
system, an evidence-based neuromodulation platform for the
treatment of chronic pain. The Senza system is the only SCS system
that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro
and the Nevro logo are trademarks of Nevro.
Investor Relations Contact:
Nevro Investor
Relations
Katherine Bock
(650) 433-3247
ir@nevro.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurosurgery-selects-the-senza-rct-24-month-outcomes-publication-as-the-top-pain-paper-of-the-year-300475084.html
SOURCE Nevro Corp.